TRIPLE THERAPY FOR CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION
Authors:
- Albert J. AugustinAAAlbert J. Augustin
- Stephan PulsSPStephan Puls
- Indre OffermannIOIndre Offermann
- 1 February 2007
- journal article
- Published by Wolters Kluwer Health in Retina
- Vol. 27 (2) , 133-140
Abstract
To evaluate the efficacy and safety of triple therapy with verteporfin photodynamic therapy (PDT), dexamethasone, and bevacizumab in choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). This prospective, noncomparative, interventional case series included 104 patients. Verteporfin PDT was administered with a reduced light dose (42 J/cm2, accomplished by light delivery time of 70 seconds). Approximately 16 hours after PDT, dexamethasone (800 μg) and bevacizumab (1.5 mg) were injected intravitreally. Patients attended follow-up visits every 6 weeks, undergoing visual acuity and intraocular pressure measurement, slit-lamp and ophthalmoscopic examination, and optical coherence tomography (OCT). Fluorescein angiography was performed every 3 months or earlier if OCT showed significant edema. All 104 patients received one triple therapy cycle (5 patients received a second triple treatment due to remaining CNV activity). The triple therapy was complemented in 18 patients (17.3%) by an additional intravitreal injection of bevacizumab. The mean follow-up period was 40 weeks (range, 22–60 weeks). Mean increase in visual acuity was 1.8 lines (P < 0.01). Mean decrease in retinal thickness was 182 μm (P < 0.01). No serious adverse events have been observed. In most patients with CNV due to AMD, triple therapy results in significant and sustained visual acuity improvement after only one cycle of treatment. In addition, the therapy offers a good safety profile, potentially lower cost compared with therapies that must be administered more frequently, and convenience for patients.Keywords
This publication has 45 references indexed in Scilit:
- Targeting angiogenesis, the underlying disorder in neovascular age-related macular degenerationCanadian Journal of Ophthalmology, 2005
- Identification of Chlamydia pneumoniae within human choroidal neovascular membranes secondary to age-related macular degenerationGraefe's Archive for Clinical and Experimental Ophthalmology, 2005
- Complement Factor H Variant Increases the Risk of Age-Related Macular DegenerationScience, 2005
- Complement Factor H Polymorphism and Age-Related Macular DegenerationScience, 2005
- The association of prior cytomegalovirus infection with neovascular age-related macular degenerationAmerican Journal of Ophthalmology, 2004
- Bedeutung oxidativer Mechanismen bei Erkrankungen der NetzhautKlinische Monatsblätter für Augenheilkunde, 2002
- Plasminogen Activators in Vascular Remodeling and AngiogenesisBiochemistry (Moscow), 2002
- Immunological and Aetiological Aspects of Macular DegenerationProgress in Retinal and Eye Research, 2001
- The Role of Oxidative Stress in the Pathogenesis of Age-Related Macular DegenerationSurvey of Ophthalmology, 2000
- The ageing retina: Physiology or pathologyEye, 1987